Mechanisms of arsenic-induced prolongation of cardiac repolarization

Molecular Pharmacology

Volumn 66, Issue 1, 2004, Pages 33-44

  Ficker, Eckhard ^a,d   Kuryshev, Yuri A ^a   Dennis, Adrienne T ^a   Obejero Paz, Carlos ^b   Wang, Lu ^a   Hawryluk, Peter ^c   Wible, Barbara A ^c   Brown, Arthur M ^a  

^a CASE WESTERN RESERVE UNIVERSITY   (United States)

^b CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c ChanTest Corporation   (United States)

^d METROHEALTH MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARSENIC TRIOXIDE; POTASSIUM CHANNEL; POTASSIUM CHANNEL HERG;

ARTICLE; CALCIUM CURRENT; CELL SURFACE; COMPLEX FORMATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EXPOSURE; DRUG FATALITY; DRUG MECHANISM; DRUG PROTEIN BINDING; HEART DEATH; HEART ELECTROPHYSIOLOGY; HEART MUSCLE POTENTIAL; HEART REPOLARIZATION; HUMAN; HUMAN CELL; LEUKEMIA REMISSION; LONG TERM EXPOSURE; PRIORITY JOURNAL; PROMYELOCYTIC LEUKEMIA; PROTEIN EXPRESSION; QT PROLONGATION; TORSADE DES POINTES;

ANIMALS; ARSENICALS; CALCIUM; ELECTROPHYSIOLOGY; ENZYME INHIBITORS; GUINEA PIGS; HEART; HEART VENTRICLES; HUMANS; MYOCYTES, CARDIAC; OXIDES; POTASSIUM CHANNELS;

EID: 3042528658     PISSN: 0026895X     EISSN: None     Source Type: Journal    
DOI: 10.1124/mol.66.1.33     Document Type: Article

References (28)

1. Balser JR (2001) The cardiac sodium channel: Gating function and molecular pharmacology. J Mol Cell Cardiol 33:599-613.
2. Barbey JT, Pezzullo JC, and Soignet SL (2003) Effect of arsenic trioxide on QT interval in patients with advanced malignancies. J Clin Oncol 21:3609-3615.
3. Berube J, Caouette D, and Daleau P (2001) Hydrogen peroxide modifies the kinetics of HERG channel expressed in a mammalian cell line. J Pharmacol Exp Ther 297:96-102.
4. Chiang CE, Luk HN, Wang TM, and Ding PYA (2002) Prolongation of cardiac repolarization by arsenic trioxide. Blood 100:2249-2252.
5. Drolet B, Simard C, and Roden DM (2004) Unusual effects of a QT-prolonging drug, arsenic trioxide, on cardiac potassium currents. Circulation 109:26-29.
6. Ficker E, Dennis AT, Wang L, and Brown AM (2003) Role of the cytosolic chaperones Hsp70 and Hsp90 in maturation of the cardiac potassium channel HERG. Circ Res 92:E87-E100.
7. Keating MT and Sanguinetti MC (2001) Molecular and cellular mechanisms of cardiac arrhythmias. Cell 104:569-580.
8. Little RE, Kay GN, Cavender JB, Epstein AE, and Plumb VJ (1990) Torsade de pointes and T-U wave alternans associated with arsenic poisoning. Pacing Clin Electrophysiol 13:164-170.
9. Liu SX, Athar M, Lippal I, Waldren C, and Hei TK (2001) Induction of oxyradicals by arsenic: implication for mechanism of genotoxicity. Proc Natl Acad Sci USA 98:1643-1648.
10. B receptor heterodimerization. Neuron 27:97-106.
11. Matsumoto S, Tanaka E, Nemoto TK, Ono T, Takagi Y, Imai J, Kimura Y, Yahara I, Kobayakawa T, Aysue T, et al. (2002) Interaction between the N-terminal and middle regions is essential for the in vivo function of Hsp90 molecular chaperone. J Biol Chem 277:34959-34966.
12. Miller WH, Schipper HM, Lee JS, Singer J, and Waxman S (2002) Mechanism of action of arsenic trioxide. Cancer Res 62:3893-3903.
13. Myers MA (1998) Direct measurement of cell numbers in microtitre plate cultures using the fluorescent dye SYBR green I. J Immunol Methods 212:99-103.
14. + channel diversity in the mammalian myocardium. J Physiol 525:285-298.
15. Ohnishi K, Yoshida H, Shigeno K, Nakamura S, Fujisawa S, Naito K, Shinjo K, Fujita Y, Matsui H, Takeshita A, et al. (2000) Prolongation of the QT interval and ventricular tachycardia in patients treated with arsenic trioxide for acute promyelocytic leukemia. Ann Intern Med 133:881-885.
16. Redfern WS, Carlsson L, Davis AS, Lynch WG, MacKenzie I, Palethorpe S, Siegl PKS, Strang I, Sullivan AT, Wallis R, et al. (2003) Relationships between preclinical cardiac electrophysiology, clinical QT interval prolongation and torsade de pointes for a broad range of drugs: evidence for a provisional safety margin in drug development. Cardiovasc Res 58:32-45.
17. Roe SM, Prodromou C, O'Brien R, Ladbury JE, Piper PW, and Pearl LH (1999) Structural basis for the inhibition of the hsp90 molecular chaperone by the antitumor antibiotics radicicol and geldanamycin. J Med Chem 42:260-266.
18. Kr potassium channel. Cell 81:299-307.
19. 3) in the treatment of acute promyelocytic leukemia (APL): II. Clinical efficacy and pharmacokinetics in relapsed patients. Blood 89:3354-3360.
20. Soignet SL, Frankel SR, Douer D, Tallman MS, Kantarjian H, Calleja E, Stone RM, Kalaycio M, Scheinberg DA, Steinherz P, et al. (2001) United States multicenter study of arsenic trioxide in relapsed acute promyelocytic leukemia. J Clin Oncol 19:3852-3860.
21. St. Petery J, Gross C, and Victoria BE (1970) Ventricular fibrillation caused by arsenic poisoning. Am J Dis Child 120:367-371.
22. + channels by reactive oxygen species. Proc Natl Acad Sci USA 94:11698-11703.
23. Unnikrishnan D, Dutcher JP, Varshneya N, Lucarielle R, Api M, Garl S, Wiernik PH, and Chiaramida S (2001) Torsade de pointes in 3 patients with leukemia treated with arsenic trioxide. Blood 97:1514-1516.
24. Westervelt P, Brown RA, Adkins DR, Khoury H, Curtin P, Hurd D, Luger SM, Ma MK, Ley TJ, and DiPersio JF (2001) Sudden death among patients with acute promyelocytic leukemia treated with arsenic trioxide. Blood 98:266-271.
25. 3 in rabbits: evidence of reversible chronic toxicity and tissue accumulation of arsenicals after parenteral administration. Toxicol Appl Pharmacol 189:214-220.
26. Zhang TD, Chen GQ, Wang ZG, Wang ZY, Chen SJ, and Chen Z (2001) Arsenic trioxide, a therapeutic agent for APL. Oncogene 20:7147-7153.
27. Zhou Z, Gong Q, Epstein ML, and January CT (1998) HERG channel dysfunction in human long QT syndrome. J Biol Chem 273:21061-21066.
28. Zhu J, Chen Z, Lallemand-Breitenbach V, and de The H (2002) How acute promyelocytic leukemia revived arsenic. Nat Rev Cancer 2:1-9.